Wimbledon Shock: Tennis Icon’s Health Battle Revealed

When Chris Evert told the world her ovarian cancer was back for a third time, she did more than cancel Wimbledon; she forced all of us to look harder at how we handle risk, truth, and courage after 70.

Story Snapshot

Chris Evert, 71, announced a third ovarian cancer recurrence after routine CT and PET scans.^[1]^[7]
She has already had surgery and will start chemotherapy, stepping away from Wimbledon and ESPN work.^[1]^[3]
Her BRCA1 gene mutation, discovered after her sister’s death, has shaped a five-year battle with cancer.^[4]^[6]
Her very public updates highlight how celebrity cancer stories inform, but often still leave key medical gaps.^[13]

A champion learns her cancer is back yet again

Chris Evert did not learn about this recurrence because she felt sick. She found it because she kept showing up for her scans. A routine computed tomography scan raised concerns, and follow-up computed tomography and positron emission tomography imaging over the weekend confirmed something was wrong. Doctors moved quickly.

She underwent exploratory surgery, and the team found her ovarian cancer had returned for the third time in five years. That is the moment she decided to tell the world herself.^[1]^[3]^[5]^[7]

Her Instagram statement was short, direct, and serious. She said she had already had surgery as the first step in treatment, and that chemotherapy would begin in the coming weeks. She also said she would miss Wimbledon and step back from other professional commitments to focus on her health.

For a woman who once ruled Center Court, that is not a small decision. It shows a clear priority: life and family over the spotlight and the schedule, which aligns with basic common sense.^[1]^[3]^[7]

How family tragedy exposed hidden genetic risk

This fight did not start in 2026. It started when her younger sister, Jeanne Evert Dubin, died of ovarian cancer in 2020. That loss pushed Chris Evert to ask hard questions. She underwent genetic testing and learned she carried a harmful BRCA1 gene mutation.

That single piece of information changed everything. Women with BRCA1 mutations face much higher lifetime risks of ovarian and breast cancer, which is why many doctors urge aggressive screening and, sometimes, preventive surgery for those patients.^[2]^[4]^[6]

In late 2021, after this genetic news, Evert’s doctors recommended major surgery to remove her ovaries, fallopian tubes, and uterus as a precaution. Pathology from that surgery stunned her team. They found stage 1 ovarian cancer in her left fallopian tube.

Because it was caught early, they could act fast. She endured another robotic surgery ten days later and six rounds of chemotherapy. Her doctors told her she had over a ninety percent chance of full recovery, which shows the power of early detection when you know your risk.^[5]^[6]

A five-year journey through remission and recurrence

By early 2023, Evert publicly said she was cancer-free and even wrote about it, stressing how key early detection had been. She also had a double mastectomy after learning more about her BRCA1 status, which further reduced her breast cancer risk. Later that same year, bad news returned.

A combined positron emission tomography and computed tomography scan showed new cancer cells in her pelvis. She underwent robotic surgery to remove them and went back on chemotherapy. That was her second battle with recurrence.^[2]^[8]

After that 2023 scare, her doctors set a strict follow-up plan. She told interviewers she was getting computed tomography scans every three months, blood tests monthly, and taking chemotherapy pills. This high level of watchfulness helped catch the 2026 recurrence quickly.

According to reporting on her latest announcement, she discovered the cancer had come back after another round of routine imaging last weekend. Many Americans skip screening because they feel fine. Her story shows how that choice can be costly when silent cancers are in play.^[1]^[2]^[5]^[8]

What the public hears, and what it does not

Most major outlets repeated the same core facts: her cancer is back, she had surgery, and chemotherapy is coming, and she will miss Wimbledon. As usual with celebrity health stories, large parts of the medical picture remain offstage.

There is no public pathology report, no scan images, and no detailed note from her oncologist laying out stage, spread, or survival odds. That privacy is her right.

At the same time, research shows many celebrity cancer stories leave out important details that would help patients understand their own situations.^[1]^[3]^[8]^[10]^[13]

"Chris Evert to miss Wimbledon after ovarian cancer recurrence" – ESPN #SmartNews https://t.co/LFkiIl51zG

— Richard Belasco (@BelascoRichard) June 26, 2026

Studies of high-profile cancer cases also show another pattern. When celebrities talk about cancer, online interest in that disease spikes sharply, and people search more for screening and treatment information.

In plain terms, Chris Evert’s announcement will likely nudge some women to ask their doctors about family history, genetic testing, and pelvic symptoms they have ignored. That is good. The challenge is ensuring the follow-up information they find is clear, honest, and grounded in real medicine, not in drama or fear.^[12]^[14]^[17]

Why this matters beyond the headlines

For readers who value personal responsibility and strong families, Evert’s choices line up with those values. She learned her inherited risk, took decisive action with surgery and screening, and kept working while she could.

She steps back only when treatment demands it, not because a network tells her to. Her path also shows why intact families and honest doctors matter. Her sister’s story, painful as it is, may have saved her life by driving her to get tested.^[2]^[6]

Her third bout with ovarian cancer raises hard questions. How many Americans with strong family cancer histories never get genetic testing. How many doctors fail to urge it because it takes time or because insurance might complain? Chris Evert’s story does not answer those policy questions.

But it presses them. A 71-year-old champion is now going through chemotherapy again because she lived long enough, and was careful enough, for her doctors to find recurrences while they were still treatable. That lesson is simple and urgent.